{
    "clinical_study": {
        "@rank": "115840", 
        "acronym": "MgNLC", 
        "arm_group": [
            {
                "arm_group_label": "MAGNOX 520\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "MAGNOX 520\u00ae (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks."
            }, 
            {
                "arm_group_label": "Similarly looking placebo.", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Similarly looking placebo. Oral administration once daily for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Nocturnal leg cramps (NLC) are painful, involuntary contractions of muscles occurring at\n      rest, mostly at night. A Cochrane review on leg cramps in pregnancy showed some potential\n      benefits in trials of magnesium. This is a single center, prospective, randomized, double\n      blind, placebo controlled clinical trial that aims to investigate the effect of treatment\n      with Magnox 520\u00ae (un-organic granular magnesium complex, composed of Magnesium Oxide &\n      Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg++) on frequency and\n      severity of NLC, quality of sleep and quality of life. Hypothesis: Magnox 520\u00ae may reduce\n      the number and severity of NLC; an improvement in the quality of life and quality of sleep\n      may ensue."
        }, 
        "brief_title": "Magnesium Oxide Monohydrate for Nocturnal Leg Cramps", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Nocturnal Leg Cramps", 
            "Quality of Life"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Muscle Cramp", 
                "Sleep-Wake Transition Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Ads in the local media and pharmacies will invite individuals afflicted by NLC to\n      participate in the study. Each participating individual will undergo two weeks of\n      eligibility screening followed by 4-week double-blind treatment. The number, severity and\n      duration of NLC will be measured daily as documented in a designated, structured sleep\n      dairy. Quality of life and quality of sleep will be assessed by SF-36 and PSQI\n      questionnaires, respectively, to be completed twice - at enrollment and within one week of\n      the end of the treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Signed informed consent before any procedure or assessment is done. Age over 21 years old.\n        Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the\n        treatment phase).\n\n        Insured by Clalit Health Services (CHS). Hebrew speaking\n\n        Exclusion Criteria:\n\n        Pregnancy Currently taking Quinidine  or Magnesium additive Renal failure - serum\n        creatinine more than 2 mg/DL or estimated glomerular filtration rate (eGFR) less than 60\n        ml/min (the worst, ascertained by the participant electronic records in the last 6\n        months). If the result is near these limits (i.e. serum creatinin 1.5-2)  a second\n        analysis will be done near the study enrollment.\n\n        Major neurological disease- ALS, MS, Paraplegia or Quadriplegia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709968", 
            "org_study_id": "Com120009ctil"
        }, 
        "intervention": {
            "arm_group_label": "MAGNOX 520\u00ae", 
            "intervention_name": "MAGNOX 520\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "MAGNOX 520\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Magnesium Oxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nocturnal Leg Cramps", 
            "Quality of life", 
            "Quality of sleep"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Haifa,", 
                    "country": "Israel"
                }, 
                "name": "Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District,"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC); a Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial.", 
        "overall_official": [
            {
                "affiliation": "Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, HAIFA, ISRAEL", 
                "last_name": "Noga Maor Rougin, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, HAIFA, ISRAEL", 
                "last_name": "Uzi Milman, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is the difference in the number of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520\u00ae and the placebo treated individuals, during a treatment period of 4 weeks;", 
            "measure": "Number of documented episodes of NLC", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709968"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Clalit Health Services", 
            "investigator_full_name": "Uzi Milman", 
            "investigator_title": "Director, Clinical Research Unit, Clalit Health Services, Haifa District, HAIFA, ISRAEL", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The difference in the severity of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520\u00ae and the placebo treated individuals, during a treatment period of 4 weeks;", 
                "measure": "Severity of documented episodes of NLC", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The difference in the duration of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520\u00ae and the placebo treated individuals, during a", 
                "measure": "Duration of documented episodes of NLC documented", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The difference in the change in quality of life (measured by SF36 at enrolment and after the treatment period) between the MAGNOX 520\u00ae and the placebo treated individuals;", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The difference in the change in quality of sleep (measured by PSQI at enrolment and after the treatment period) between the MAGNOX 520\u00ae and the placebo treated individuals;", 
                "measure": "Quality of sleep", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Clalit Health Services", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Uzi Milman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014", 
        "why_stopped": "Blinded interim analysis was presented to an independent data monitoring committee.\n    Recommendation, submitted April 1, 2014, was early termination for futility."
    }
}